Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?

Arthritis and Rheumatism

Volumn 63, Issue 2, 2011, Pages 325-328

  Teitelbaum, Steven L ^a   Seton, Margaret P ^b   Saag, Kenneth G ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; GLUCOCORTICOID; PARATHYROID HORMONE[1-34];

BONE DENSITY; BONE MASS; BONE REMODELING; FRACTURE; HUMAN; LONG TERM CARE; NOTE; OSTEOPOROSIS; PRIORITY JOURNAL;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RHEUMATIC DISEASES;

EID: 79551672353     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30135     Document Type: Note

References (40)

1. Raisz LG,. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-25.
2. Parfitt AM, Villanueva AR, Foldes J, Rao DS,. Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res 1995; 10: 466-73.
3. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996; 81: 3366-71.
4. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-99.
5. Weinstein RS,. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001; 2: 65-73.
6. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC,. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 1998; 102: 274-82.
7. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP,. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991; 72: 382-6.
8. Dempster DW,. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989; 4: 137-41.
9. Ton FN, Gunawardene SC, Lee H, Neer RM,. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005; 20: 464-70.
10. Rackoff PJ, Rosen CJ,. Pathogenesis and treatment of glucocorticoid- induced osteoporosis. Drugs Aging 1998; 12: 477-84.
11. Ruegsegger P, Medici TC, Anliker M,. Corticosteroid-induced bone loss: a longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983; 25: 615-20.
12. Leonard MB,. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007; 119 Suppl 2: S166-74.
13. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A,. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006; 17: 144-9.
14. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002; 109: 1041-8.
15. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496-503.
16. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 244: 271-92. (Pubitemid 28473991)
17. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006; 116: 2152-60.
18. Hong JM, Kim TH, Ross FP, Teitelbaum SL, Kim SY, Kim HJ,. Calpain 6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation. J Bone Miner Res 2010. E-pub ahead of print.
19. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE,. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008; 58: 1674-86.
20. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006; 21: 292-9.
21. Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18: 919-24.
22. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-39.
23. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al, for the Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-9.
24. Drake MT, Clarke BL, Khosla S,. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83: 1032-45.
25. Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP,. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004; 15: 992-7.
26. Seeman E, Delmas PD,. Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250-61.
27. Hruska KA, Teitelbaum SL,. Renal osteodystrophy. N Engl J Med 1995; 333: 166-74.
28. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C,. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48: 3224-9.
29. Allen MR, Burr DB,. Mineralization, microdamage, and matrix: how bisphosphonates influence material properties of bone. BoneKEy-Osteovision 2007; 4: 49-60.
30. Allen MR, Burr DB,. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007; 22: 1759-65.
31. O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg 2009; 67: 1363-72.
32. Lenart BA, Lorich DG, Lane JM,. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358: 1304-6.
33. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY,. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-301.
34. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009; 85: 37-44.
35. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010. E-pub ahead of print.
36. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60: 3346-55.
37. Eastell R, Chen P, Saag KG, Burshell AL, Wong M, Warner MR, et al. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 2010; 46: 929-34.
38. Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 2010; 37: 141-8.
39. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010; 69: 872-5.
40. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25: 72-81.